Insulin sensitizers in treatment of nonalcoholic fatty liver disease.
- VernacularTitle:胰岛素增敏剂防治非酒精性脂肪性肝病临床价值
- Author:
Hongmei YAN
;
Xin GAO
- Publication Type:Journal Article
- Keywords:
nonalcoholic fatty liver disease;
insulin resistance;
insulin sensitizer
- From:
Chinese Journal of Practical Internal Medicine
2001;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Nonalcoholic fatty liver disease(NAFLD)has become one of the most common liver diseases in the world.Considering the important role of insulin resistance in its pathogenic mechanisms,insulin sensitizers are becoming the promising pharmacological strategies for NAFLD.We collected and analyzed the relevant articles in recent years and found that pioglitazone,rosiglitazone and metformin could improve liver enzymes and insulin sensitivity of NAFLD.However,only pioglitazine was supported in ameliorating liver histology by envidences from randomized,double-blinded,controlled clinical trials.There were no much obvious adverse effects in NAFLD patients who received insulin senitizers.Small or medium samples and no more than 2 years of treatment course may be the major limitation of current studies.Future information derived from well-designed running trials will be useful in defining the clinical implications of insulin sensitizers in the treatment of NAFLD.
